Dravet syndrome is one of the most severe forms of epilepsy in existence. It begins in the first year of life, usually with a prolonged seizure triggered by fever. From there, it progresses to multiple seizure types, intellectual disability, behavioural difficulties, and a significantly elevated risk of sudden unexpected death in epilepsy (SUDEP). Most children with Dravet syndrome have been resistant to conventional anti-epileptic drugs — some families manage dozens of seizures a week, for years, with no relief in sight.
New clinical trial results for a drug called **zorevunersen** have produced numbers that parents and neurologists are describing as life-changing: a reduction in seizures of up to **91%**.
**What Is Dravet Syndrome?**
Dravet syndrome is caused by a mutation in the *SCN1A* gene, which encodes a sodium channel critical to the function of inhibitory neurons in the brain. When this channel is faulty, inhibitory neurons fire poorly, the brain becomes hyperexcitable, and seizures result — often long, convulsive, and dangerous.
The condition affects roughly 1 in 15,000 to 1 in 20,000 children. Until recently, treatment options were limited to anticonvulsants that reduced — but rarely controlled — seizures, and which often came with significant side effects. A few newer options, including cannabidiol and fenfluramine, have helped some patients, but a significant proportion remain poorly controlled.
For decades, families with a child diagnosed with Dravet syndrome have been told there is no cure, no highly effective treatment, and to expect a life of medical complexity, school challenges, and danger.
**Zorevunersen: A New Approach**
Zorevunersen works differently from conventional anticonvulsants. Rather than broadly suppressing neuronal activity across the brain, it is an **antisense oligonucleotide (ASO)** — a short strand of modified genetic material designed to bind specifically to RNA transcripts in the cell and modify how the *SCN1A* gene is expressed.
In Dravet syndrome, the faulty copy of *SCN1A* is only one of two copies — the other typically remains functional. Zorevunersen is designed to upregulate the expression of the working copy, effectively compensating for the broken one. It addresses the root cause of the condition at the molecular level, rather than simply managing symptoms.
**The Trial Results**
In clinical trials presented in March 2026, zorevunersen achieved results that stunned the epilepsy community:
- Seizure frequency reduced by **up to 91%** in responding patients - Many families reported weeks — in some cases months — of near-complete seizure freedom, something previously unimaginable - Quality of life scores improved dramatically for both children and their caregivers - The drug was administered via intrathecal injection (directly into the spinal canal), and the results were maintained over the trial period
For families who had endured years of daily seizures and emergency hospital visits, the shift was described as transformative. One parent, whose child had previously experienced multiple seizures daily, described the change as 'getting our child back.'
**The Road Ahead**
Zorevunersen is not yet approved — regulatory review is ongoing, and the drug will need to complete additional trials before it becomes widely available. But the results from these trials represent a clinical and scientific milestone: the first time a treatment has produced this magnitude of seizure reduction in a condition that has, for most patients, been effectively untreatable.
The broader field of ASO therapies has had remarkable recent successes — in spinal muscular atrophy, Huntington's disease, and now Dravet syndrome. The principle of targeting disease at the genetic transcript level, rather than managing downstream symptoms, is proving more and more powerful as the technology matures.
For children with Dravet syndrome and their families, who have lived with uncertainty and fear for so long, the results offer something that has been in short supply: genuine, evidence-based hope. 🧠💙
*Sources: Science Daily · Dravet Syndrome Foundation · MedPage Today · Neurology Today · Drug Discovery News · Epilepsy Foundation*
